BioPlus Acquisition Corp. Unit
BIOSU
BIOSU was delisted on the 6th of October, 2023.
2 hedge funds and large institutions have $210K invested in BioPlus Acquisition Corp. Unit in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.
11% more capital invested
Capital invested by funds: $188K → $210K (+$21.2K)
0% more funds holding
Funds holding: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
+$205K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$540 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$186K |
BIOSU Hedge Fund Activity: Q3 2023 in Review
2 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in BioPlus Acquisition Corp. Unit (BIOSU) for Q3 2023, worth a combined $210K — up 11% from $188K a quarter earlier.
Fund positioning in BIOSU was balanced in Q3 2023: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Clear Street, adding an estimated $205K. The largest seller was State Street, exiting entirely with an estimated $186K sold.
- 2 institutional investors held BioPlus Acquisition Corp. Unit (BIOSU) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $210K of BioPlus Acquisition Corp. Unit stock for Q3 2023, up 11% quarter-over-quarter.
- 1 fund opened new BioPlus Acquisition Corp. Unit positions in Q3 2023 and 1 closed out, a net change of 0 holders.
- The largest BioPlus Acquisition Corp. Unit buyer in Q3 2023 was Clear Street, an estimated $205K added.
- The largest BioPlus Acquisition Corp. Unit seller in Q3 2023 was State Street, an estimated $186K sold.
Based on aggregated 13F filings for Q3 2023.